السوق العالمية لاختبارات التسلسل الجيني للجيل التالي (NSG) – اتجاهات الصناعة والتوقعات حتى عام 2028

تحليل السوق ورؤى حول سوق اختبارات التسلسل الجيني للجيل التالي (NSG) السريرية

إن التقدم التكنولوجي في اختبارات التسلسل الجيني للجيل التالي (NSG) السريرية إلى جانب ارتفاع مهارات البحث والتطوير يعزز نمو السوق. تحلل شركة Data Bridge Market Research أن سوق اختبارات التسلسل الجيني للجيل التالي (NSG) السريرية سيظهر معدل نمو سنوي مركب يبلغ حوالي 27.25٪ للفترة المتوقعة من 2021 إلى 2028.

اختبار التسلسل الجيني للجيل التالي (NSG) هو اختبار وضع التسلسل الجيني في الممارسة السريرية. يسمح اختبار التسلسل الجيني للجيل التالي (NSG) للأطباء أو المعالجين السريريين باختبار الجينات ومراقبتها. يساعد في اكتشاف وتحديد ترتيب الأدينين والجوانين والسيتوزين والثايمين. تساعد هذه التقنية في تحديد السبب في إطار زمني مخفض وبالتالي تحسين كفاءة ممارسات الرعاية الصحية.

لقد عزز الوعي المتزايد بفوائد تقنية اختبار التسلسل الجيني للجيل التالي (NSG) السريرية نمو الطلب عليها. كما أن نمو وتوسع صناعة الجينوم في جميع أنحاء العالم يعزز أيضًا نمو تقنية اختبار التسلسل الجيني للجيل التالي (NSG) السريرية. ومن شأن مبادرات البحث والتطوير الحكومية المتزايدة أن تعمل على توسيع نطاق نمو السوق.

ومع ذلك، فإن المشاكل في تحليلات البيانات أثناء إجراء تسلسل الخلية الواحدة من شأنها أن تبطئ نمو السوق. كما أن القاعدة التكنولوجية منخفضة الدرجة، وخاصة في الاقتصادات غير المتقدمة، من شأنها أن تزيد من تباطؤ معدل نمو السوق. كما أن الصعوبة في إدارة البيانات الضخمة والمركبة ستشكل تحديًا للسوق.

This clinical next-generation sequencing (NSG) testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on clinical next-generation sequencing (NSG) testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Clinical Next-Generation Sequencing (NSG) Testing Market Scope and Market Size

The clinical next-generation sequencing (NSG) testing market is segmented on the basis of technology, application, end user, service and workflow. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of technology, the clinical next-generation sequencing (NSG) testing market is segmented into sequencing by synthesis, ion semiconductor sequencing, single- molecule real-time sequencing, Nano pore sequencing and other sequencing technologies.
• On the basis of application, the clinical next-generation sequencing (NSG) testing market is segmented into diagnostics, drug discovery, agricultural and animal research and other applications. Diagnostics is further sub-segmented into cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics and other diagnostic applications.
• On the basis of end user, the clinical next-generation sequencing (NSG) testing market is segmented into academic institutes and research centres, hospitals and clinics, pharmaceutical and biotechnology companies and other end users.
• The clinical next-generation sequencing (NSG) testing market is also segmented on the basis of service into human genome sequencing, single cell sequencing, microbial genome- based sequencing, gene regulation services, animal and plant sequencing and other sequencing services.
• On the basis of workflow, the clinical next-generation sequencing (NSG) testing market is segmented into pre-sequencing, sequencing and data analysis.

Clinical Next-Generation Sequencing (NSG) Testing Market Country Level Analysis

The clinical next-generation sequencing (NSG) testing market is analysed and market size insights and trends are provided by country, technology, application, end user, service and workflow as referenced above.

The countries covered in the clinical next-generation sequencing (NSG) testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the clinical next-generation sequencing (NSG) testing market. The presence of major key players using clinical next-generation sequencing (NSG) testing technology is driving the growth of the market in this region. Asia-Pacific on the other hand will project the highest growth rate during the forecast period owing to the rising government initiatives to boost up the genomics industry.

The country section of the clinical next-generation sequencing (NSG) testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Clinical Next-Generation Sequencing (NSG) Testing Market Share Analysis

The clinical next-generation sequencing (NSG) testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to clinical next-generation sequencing (NSG) testing market.

اللاعبون الرئيسيون الذين تم تغطيتهم في تقرير سوق اختبار تسلسل الجيل التالي السريري (NSG) هم 3billion، Inc.، و10x Genomics.، و23andMe، Inc.، وAdmera Health، وAgilent Technologies، Inc.، وALCEN، وAlmac Group، وAMARANTUS BIOSCIENCE HOLDINGS، INC.، وAmbry Genetics.، وAperiomics، Inc.، وARUP Laboratories.، وASURAGEN، INC.، وAthena Diagnostics، Inc.، وAtreca، Inc.، وBase4، وBaylor Genetics، وBD، وBerry Gene، وBGI، وBioarray SL، وBiodesix.، وBoreal Genomics Inc. وCambridge Epigenetix Limited من بين لاعبين محليين وعالميين آخرين. تتوفر بيانات حصة السوق للعالم وأمريكا الشمالية وأوروبا وآسيا والمحيط الهادئ (APAC) والشرق الأوسط وأفريقيا (MEA) وأمريكا الجنوبية بشكل منفصل. يفهم محللو DBMR نقاط القوة التنافسية ويوفرون تحليلاً تنافسيًا لكل منافس على حدة.

SKU-34903